Rare kidney & urinary condition
Von Hippel-Lindau disease: kidney surveillance
Von Hippel-Lindau disease carries a lifetime kidney cancer risk approaching 70%, managed not by removing kidneys but by lifelong imaging surveillance and intervening only when tumours reach 3 cm - with a new drug option now available.
Key points
The essentials at a glance.
What to look out for, how the diagnosis is confirmed, who looks after it, and the options that exist.
-
01
VHL kidney cancers are typically multiple, bilateral and recurring - the strategy is control, not eradication.
-
02
Annual abdominal imaging (MRI preferred) is standard from the mid-teens.
-
03
The 3 cm rule: solid tumours are watched until they reach about 3 cm, then removed by kidney-sparing surgery or ablation - metastasis below that size is rare.
-
04
Belzutifan, an oral HIF-2α inhibitor, is licensed for VHL-associated tumours and can shrink kidney lesions, reducing the need for repeated surgery.
-
05
Care belongs in specialist VHL/genetics services coordinating kidney, brain, eye, adrenal and pancreas surveillance.
Understanding it
What it is, and what happens next.
In plain English - what is going on, how specialists confirm it, and the routes to treatment in the UK.
VHL disease disables the cell's oxygen-sensing brake, and clear cell kidney cancers arise throughout both kidneys across a lifetime. The management philosophy matured through hard experience: radical nephrectomies traded cancer for dialysis, whereas active surveillance with the 3 cm threshold preserves kidney function for decades while keeping metastatic risk very low - a discipline that only works when imaging is never skipped.
Adults with VHL should sit inside a formal surveillance programme - annual MRI, coordinated with the eye, brain and endocrine screening the syndrome also demands - with intervention decisions made by urologists experienced in nephron-sparing approaches; belzutifan has added a genuine systemic option, shrinking tumours pharmacologically and deferring operations, under specialist oversight. In many parts of the UK, routine NHS outpatient referrals for problems like this can take several months, whereas an initial appointment with a private consultant is typically available within around two weeks.
A quiet reminder
This guide is for information, not medical advice.
Your GP or specialist knows your history and can tell you which parts apply to you. If in doubt, speak to them.
Published 2026-09-27 · Next review 2027-09-27
Frequently asked
Common questions about Von Hippel-Lindau disease: kidney surveillance.
Quick, plain-English answers to what people ask us most.
-
What is kidney surveillance in Von Hippel-Lindau disease?
It is a programme of regular imaging to monitor for kidney tumours (renal cell carcinoma) and cysts, which are common features of Von Hippel-Lindau (VHL) disease, allowing early detection and treatment.
-
Why is kidney surveillance needed in VHL disease?
People with VHL disease have a significantly increased lifetime risk of developing kidney cancer, often at a younger age than the general population, and regular surveillance allows tumours to be caught and treated while still small, helping to preserve kidney function.
-
What does kidney surveillance typically involve?
Regular imaging, usually MRI or ultrasound, of the kidneys, often starting in the teenage years and continuing throughout adult life at intervals recommended by a specialist familiar with VHL disease.
-
Is kidney cancer in VHL disease dangerous?
It can be, though the approach of regular surveillance and early treatment when tumours reach a certain size threshold significantly reduces the risk of the cancer spreading, while also aiming to preserve as much healthy kidney tissue as possible.
-
Can VHL-related kidney tumours be treated?
Yes, small tumours are monitored, while larger ones (typically over 3cm) are usually treated with kidney-sparing surgery to remove the tumour while preserving as much normal kidney tissue as possible, given that new tumours can develop over time.
-
How often is surveillance imaging needed?
This is individualised but often involves annual or biennial imaging, with the specific schedule tailored by a specialist familiar with VHL disease based on findings and personal risk.
-
How is the decision made about when to treat a kidney tumour?
Treatment is generally considered once a tumour reaches a certain size threshold, commonly around 3cm, balancing the need to prevent cancer spread against preserving kidney function for what is often a lifelong condition needing repeated interventions.
-
VHL-related kidney tumours vs sporadic kidney cancer - what's the difference?
VHL-related kidney tumours tend to occur at a younger age, are often multiple, and recur over time due to the underlying genetic condition, requiring a different, ongoing surveillance and treatment strategy compared with a single sporadic kidney cancer in someone without VHL disease.
-
When should I see a specialist about VHL kidney surveillance, and how quickly can this be arranged privately?
Ongoing specialist urology or genetics follow-up is essential for anyone with VHL disease. NHS specialist clinics can have waits; private specialists experienced in VHL can often see you within about two weeks.